ScripThe high cost of living is a reality many grapple with, and biotechs are no exception. Medigene and Idorsia are active in very different therapeutic areas but have butted up against similar difficulti
ScripDespite apparent lingering caution on the part of some biopharma multinationals over additional investments in China, Bayer and Eli Lilly have over the past few months both made similar moves to put n
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. OcuMension Signs Stock-for-Rights
In VivoGerman biotech Medigene AG is focused on developing T-cell receptor engineered T-cell (TCR-T) therapies for the treatment of solid tumors. After $29.4m was raised in 2022, a further $6.3m this year